Exclusive TCRVβ chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: Implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping

Rob M. Verdijk; Tuna Mutis; Martina Wilke; Jos Pool; Ellen Schrama; Anneke Brand; Els Goulmy

doi:https://doi.org/10.1038/sj.thj.6200197

Exclusive TCRVβ chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: Implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping

Rob M. Verdijk, Tuna Mutis, Martina Wilke, Jos Pool, Ellen Schrama, Anneke Brand, Els Goulmy

Research output: Contribution to journal › Article › Academic › peer-review

15 Citations (Scopus)

Abstract

Tissue expression of minor Histocompatibility antigens HA-1 and HA-2 is limited to the hematopoietic system. Therefore, ex vivo generated HA-1/HA-2 specific cytotoxic T lymphocytes (CTLs) can be applied for adoptive immunotherapy of relapsed leukemia after HLA-matched HA-1/HA-2 mismatched stem cell transplantation. Here we used T cell receptor β variable chain (TCRBV) spectratyping and/or TCRBV sequencing to monitor the specific TCR usage in eleven HA-1/HA-2 CTLs that were induced ex vivo with peptide pulsed dendritic cells. The HA-2 induced CTLs used different TCRBV. In contrast, the development of HA-1 specific CTLs coincided with prominent skewing of TCRBV7 spectratypes. Sequencing of the TCRBV7 specific PCR products used by these ex vivo generated HA-1 CTLs revealed the exclusive usage of TCRBV7-9*03, identical to the TCRBV used by HA-1 specific CTLs induced in vivo after stem cell transplantation. Thus, monitoring of immunotherapy with HA-1 specific CTLs is now also feasible by TCRBV spectratyping.

Original language	English
Pages (from-to)	271-275
Number of pages	5
Journal	hematology journal
Volume	3
Issue number	6
DOIs	https://doi.org/10.1038/sj.thj.6200197
Publication status	Published - 1 Dec 2002

Keywords

Human
Immunotherapy
Minor histocompatibility antigen
Spectratype
T cell receptor variable beta chain

Access to Document

https://doi.org/10.1038/sj.thj.6200197

Cite this

@article{0d3c0accd9b74049ac2be680b7c50955,

title = "Exclusive TCRVβ chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: Implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping",

abstract = "Tissue expression of minor Histocompatibility antigens HA-1 and HA-2 is limited to the hematopoietic system. Therefore, ex vivo generated HA-1/HA-2 specific cytotoxic T lymphocytes (CTLs) can be applied for adoptive immunotherapy of relapsed leukemia after HLA-matched HA-1/HA-2 mismatched stem cell transplantation. Here we used T cell receptor β variable chain (TCRBV) spectratyping and/or TCRBV sequencing to monitor the specific TCR usage in eleven HA-1/HA-2 CTLs that were induced ex vivo with peptide pulsed dendritic cells. The HA-2 induced CTLs used different TCRBV. In contrast, the development of HA-1 specific CTLs coincided with prominent skewing of TCRBV7 spectratypes. Sequencing of the TCRBV7 specific PCR products used by these ex vivo generated HA-1 CTLs revealed the exclusive usage of TCRBV7-9*03, identical to the TCRBV used by HA-1 specific CTLs induced in vivo after stem cell transplantation. Thus, monitoring of immunotherapy with HA-1 specific CTLs is now also feasible by TCRBV spectratyping.",

keywords = "Human, Immunotherapy, Minor histocompatibility antigen, Spectratype, T cell receptor variable beta chain",

author = "Verdijk, {Rob M.} and Tuna Mutis and Martina Wilke and Jos Pool and Ellen Schrama and Anneke Brand and Els Goulmy",

year = "2002",

month = dec,

day = "1",

doi = "https://doi.org/10.1038/sj.thj.6200197",

language = "English",

volume = "3",

pages = "271--275",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "6",

}

Exclusive TCRVβ chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: Implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping. / Verdijk, Rob M.; Mutis, Tuna; Wilke, Martina et al.
In: hematology journal, Vol. 3, No. 6, 01.12.2002, p. 271-275.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Exclusive TCRVβ chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells

T2 - Implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping

AU - Verdijk, Rob M.

AU - Mutis, Tuna

AU - Wilke, Martina

AU - Pool, Jos

AU - Schrama, Ellen

AU - Brand, Anneke

AU - Goulmy, Els

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Tissue expression of minor Histocompatibility antigens HA-1 and HA-2 is limited to the hematopoietic system. Therefore, ex vivo generated HA-1/HA-2 specific cytotoxic T lymphocytes (CTLs) can be applied for adoptive immunotherapy of relapsed leukemia after HLA-matched HA-1/HA-2 mismatched stem cell transplantation. Here we used T cell receptor β variable chain (TCRBV) spectratyping and/or TCRBV sequencing to monitor the specific TCR usage in eleven HA-1/HA-2 CTLs that were induced ex vivo with peptide pulsed dendritic cells. The HA-2 induced CTLs used different TCRBV. In contrast, the development of HA-1 specific CTLs coincided with prominent skewing of TCRBV7 spectratypes. Sequencing of the TCRBV7 specific PCR products used by these ex vivo generated HA-1 CTLs revealed the exclusive usage of TCRBV7-9*03, identical to the TCRBV used by HA-1 specific CTLs induced in vivo after stem cell transplantation. Thus, monitoring of immunotherapy with HA-1 specific CTLs is now also feasible by TCRBV spectratyping.

AB - Tissue expression of minor Histocompatibility antigens HA-1 and HA-2 is limited to the hematopoietic system. Therefore, ex vivo generated HA-1/HA-2 specific cytotoxic T lymphocytes (CTLs) can be applied for adoptive immunotherapy of relapsed leukemia after HLA-matched HA-1/HA-2 mismatched stem cell transplantation. Here we used T cell receptor β variable chain (TCRBV) spectratyping and/or TCRBV sequencing to monitor the specific TCR usage in eleven HA-1/HA-2 CTLs that were induced ex vivo with peptide pulsed dendritic cells. The HA-2 induced CTLs used different TCRBV. In contrast, the development of HA-1 specific CTLs coincided with prominent skewing of TCRBV7 spectratypes. Sequencing of the TCRBV7 specific PCR products used by these ex vivo generated HA-1 CTLs revealed the exclusive usage of TCRBV7-9*03, identical to the TCRBV used by HA-1 specific CTLs induced in vivo after stem cell transplantation. Thus, monitoring of immunotherapy with HA-1 specific CTLs is now also feasible by TCRBV spectratyping.

KW - Human

KW - Immunotherapy

KW - Minor histocompatibility antigen

KW - Spectratype

KW - T cell receptor variable beta chain

UR - http://www.scopus.com/inward/record.url?scp=0036972301&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/sj.thj.6200197

DO - https://doi.org/10.1038/sj.thj.6200197

M3 - Article

C2 - 12522448

SN - 0390-6078

VL - 3

SP - 271

EP - 275

JO - Haematologica

JF - Haematologica

IS - 6

ER -

Exclusive TCRVβ chain usage of ex vivo generated minor Histocompatibility antigen HA-1 specific cytotoxic T cells: Implications for monitoring of immunotherapy of leukemia by TCRBV spectratyping

Abstract

Keywords

Access to Document

Other files and links

Cite this